The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies
Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (MTOR) pathway hyperactivation is seen in a multitude of malignancies. Due to the importance of this pathway in numerous critical cellular functions, preclinical and clinical investigations have aimed to target this pathway as an...
Saved in:
Main Authors: | Alexa E. Schmitz, Shirsa Udgata, Katherine A. Johnson, Dustin A. Deming |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-05-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/13/6/1319 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Esculetin inhibits the PI3K/Akt/mTOR pathway and enhances anti-colorectal cancer activity via binding to ENO1
by: Jianing Ma, et al.
Published: (2025-07-01) -
Synergistic Antitumor Effects of Ivermectin and Metformin in Canine Breast Cancer via PI3K/AKT/mTOR Pathway Inhibition
by: Huili Feng, et al.
Published: (2025-05-01) -
Plinabulin exerts an anti-proliferative effect via the PI3K/AKT/mTOR signaling pathways in glioblastoma
by: Rouxin Wang, et al.
Published: (2025-01-01) -
Salidroside inhibits melanin synthesis and melanoma growth via mTOR and PI3K/Akt pathways
by: Qi Ouyang, et al.
Published: (2025-07-01) -
ARF6 Promotes AML Progression via Activation of PI3K/AKT/mTOR Signaling
by: Haitao Xu, et al.
Published: (2025-05-01)